Combination inhaled bronchodilator therapy in the management of chronic obstructive pulmonary disease

Pharmacotherapy

Volumn 27, Issue 3, 2007, Pages 447-454

  Nichols, Jake ^a,b  

^a UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^b Commonwealth Medicine ^*  (United States)

Author keywords

Albuterol; Bronchodilators; Chronic obstructive pulmonary disease; COPD; Formoterol; GOLD guidelines; Ipratropium; Salmeterol; Tiotropium

Indexed keywords

BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BRONCHODILATING AGENT; CHOLINERGIC RECEPTOR BLOCKING AGENT; CORTICOSTEROID; FORMOTEROL; IPRATROPIUM BROMIDE; IPRATROPIUM BROMIDE PLUS SALBUTAMOL SULFATE; LEVALBUTEROL; OXITROPIUM BROMIDE; PIRBUTEROL; SALBUTAMOL; SALMETEROL; THEOPHYLLINE; TIOTROPIUM BROMIDE;

BRONCHODILATATION; CHRONIC OBSTRUCTIVE LUNG DISEASE; DISEASE EXACERBATION; DRUG EFFICACY; HUMAN; OUTCOMES RESEARCH; PATIENT COMPLIANCE; PRACTICE GUIDELINE; PRESCRIPTION; SHORT SURVEY; SYMPTOMATOLOGY; SYSTEMATIC REVIEW;

ADMINISTRATION, INHALATION; ALBUTEROL; BRONCHODILATOR AGENTS; DRUG THERAPY, COMBINATION; ETHANOLAMINES; HUMANS; IPRATROPIUM; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; SCOPOLAMINE DERIVATIVES;

EID: 33847313718     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.27.3.447     Document Type: Short Survey

References (24)

1. National Center for Health Statistics. Report of final mortality statistics, 2002. Available from http://www.cdc.gov/nchs/deaths.htm. Accessed May 8, 2006.
2. National Center for Health Statistics. Raw data from the national health interview survey U.S., 2002. Available from http://www.cdc.gov/nchs/nhis. htm. Accessed May 8, 2006.
3. United States Department of Health and Human Services. The health consequences of smoking: a report of the surgeon general, 2004. Available from http://www.surgeongeneral.gov/tobacco/. Accessed May 8, 2006.
4. National Heart Lung and Blood Institute. Morbidity and mortality chartbook, 2004. Available from http://www.nhlbi.nih .gov/resources/docs/cht- book.htm. Accessed May 8, 2006.
5. Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: executive summary updated 2005. Available from http://www.goldcopd.com. Accessed May 8, 2006.
6. Guyatt GH, Townsend M, Pugsley SO, et al. Bronchodilators in chronic airflow limitation: effects on airway function, exercise capacity, and quality of life. Am Rev Respir Dis 1987;135:1069-74.
7. Belman MJ, Botnik WC, Shin JW. Inhaled bronchodilators reduce hyperinflation during exercise in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1996;153:967-75.
8. O'Donnell DE, Lam M, Webb KA. Spirometric correlates of improvement in exercise performance after anticholinergic therapy in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1999;160:542-9.
9. Tashkin DP, Cooper CB. The role of long-acting bronchodilators in the management of stable COPD. Chest 2004;125:249-59.
10. Zuwallack RL, Mahler DA, Reilly D, et al. Salmeterol plus theophylline combination therapy in the treatment of COPD. Chest 2001;119:1661-70.
11. Hanania NA, Darken P, Horstman D, et al. The efficacy and safety of fluticasone propionate (250 micrograms)/salmeterol (50 micrograms) combined in the Diskus inhaler for the treatment of COPD. Chest 2003;124:834-43.
12. Calverley P, Pauwels R, Vestbo J, et al. Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial. Lancet 2003;361:449-56.
13. van Noord JA, Bantje TA, Eland ME, Korducki L, Cornelissen PJ. A randomised controlled comparison of tiotropium and ipratropium in the treatment of chronic obstructive pulmonary disease. Thorax 2000;55:289-94.
14. Vincken W, van Noord JA, Greefhorst AP, et al. Improved health outcomes in patients with COPD during 1 yr's treatment with tiotropium. Eur Respir J 2002;19:209-16.
15. Combivent Aerosol Study Group. In chronic obstructive pulmonary disease, a combination of ipratropium and albuterol is more effective than either agent alone: an 85-day multicenter trial. Chest 1994;105:1411-19.
16. Wilson JD, Serby CW, Menjoge SS, Witek TJ Jr. The efficacy and safety of combination bronchodilator therapy. Eur Respir Rev 1996;39:286-9.
17. Kleerup EC, Dauphinee MA, Flanders JS, et al. The combination of ipratropium and albuterol in a single inhaler is more effective than albuterol alone for bronchodilation in patients with chronic obstructive pulmonary disease. Chest 1995;108:107S.
18. Matera MG, Caputi M, Cazzola M. A combination with clinical recommended dosages of salmeterol and ipratropium is not more effective than salmeterol alone in patients with chronic obstructive pulmonary disease. Respir Med 1996;90:497-9.
19. van Noord JA, de Munck DRAJ, Bantje T, et al. Long-term treatment of chronic obstructive pulmonary disease with salmeterol and the additive effect of ipratropium. Eur Respir J 2000;15:878-85.
20. Chapman KR, Arvidsson P, Chuchalin AG, et al. The addition of salmeterol 50 meg BID to anticholinergic treatment in patients with COPD: a randomized, placebo controlled trial. Can Respir J 2002;9:178-85.
21. Cazzola M, DiMarco F, Santus P, et al. The pharmacodynamic effects of single inhaled doses of formoterol, tiotropium, and their combination in patients with COPD. Pulm Pharmacol Ther 2004;17:35-9.
22. van Noord JA, Aumann JL, Janssens E, et al. Effects of tiotropium with and without formoterol on airflow obstruction and resting hyperinflation in patients with COPD. Chest 2006;129:509-17.
23. Cazzola M, Centanni S, Santus P, et al. The functional impact of adding salmeterol and tiotropium in patients with stable COPD. Respir Med 2004;98:1214-21.
24. Baloria VA, Vilarino PC. Bronchodilator efficacy of combined salmeterol and tiotropium in patients with chronic obstructive pulmonary disease. Arch Bronchopneumol 2005;41:130-4.